Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today released its environmental,
social and governance (ESG) report for 2023, highlighting Twist’s
approach to sustainability, social responsibility and commitment to
ethics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230822647314/en/
Visual comparison of emissions equivalent
from manufacturing a single gene using Twist Bioscience's approach
versus manufacturing a single gene using a 96-well plate approach
(Graphic: Business Wire)
“We took a big step forward in our ongoing commitment to deliver
sustainable solutions to our customers, quantifying the impact of
our proprietary approach to making synthetic DNA,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Last year
we quantified our chemical footprint and found that our silicon
chip-based approach to creating DNA uses 99.8% fewer chemicals than
96-well plate approaches1. This year, we’ve quantified the carbon
footprint of manufacturing a single Twist gene compared to
manufacturing a gene using a 96-well plate approach and the results
are dramatic. Manufacturing one gene using the Twist method is
equivalent to the emissions from driving a gas car 0.092 miles or
0.15 kilometers2. The amount of CO2e emitted using a standard
96-well plate approach is equivalent to driving 59 miles or 96
kilometers. The more sustainable synthetic DNA we provide to our
customers is not new; we have just quantified the emissions impact
of our proprietary approach, which then carries through to all of
our customers who use our DNA for new therapies, diagnostic tests,
materials, biobased chemicals, and more.”
Dr. Leproust continued, “In addition to the quantification data,
we continue to exemplify good environmental, social and governance
practices. We joined the United Nations Global Compact and
committed to Sustainable Development Goals focused on
sustainability, food security, health and gender equality. As a
company, we continue to foster a diverse workforce and support
career growth and development while running an ethical business
with cyber and biosecurity measures in place.”
Sustainable Platform and Minimal Carbon Footprint
Twist has quantified the carbon footprint of manufacturing a
single gene using its silicon chip-based platform compared to
approaches that use a 96-well plate. Twist’s approach emits 36
grams (0.036 kilograms) of carbon dioxide equivalent (CO2e) per
gene, compared to up to 23,000 grams (23 kilograms) per gene
emitted by 96-well plate approaches1. The calculation to determine
the carbon footprint of Twist’s process is validated by two
independent consulting firms, Silinnov and SRI Quality System
Registrar.
Beyond the sustainability of its platform, Twist has several
internal recycling programs to reduce waste from nitrile gloves and
plastic tip boxes. In 2022 Twist diverted 7,745 pounds of nitrile
glove waste from landfills and diverted more than 21,760 pounds of
waste since starting the program. As a result of its plastic tip
recycling program, Twist diverted 7,635 pounds of single-use
plastics from landfills. In 2023, Twist updated its packing
materials with recyclable coolers and boxes made from 50% recycled
material.
Fostering a Diverse Workforce
Twist continues to foster a diverse, inclusive and safe work
environment. As of the end of fiscal 2022, 61% of Twist’s workforce
identified as people of color, with women of color making up 25% of
the organization3. Women make up 41% of the total workforce at
Twist, and are well represented in leadership positions, accounting
for 39% of the executive team and 33% of the Board of Directors.
Twist is committed to diversity in its recruitment efforts and
engages in partnerships with local community colleges in
California, Oregon and Massachusetts.
Twist invests in developing talent, offering a year-long
leadership program for mid-level managers and tuition reimbursement
of up to $5,250 per year for all employees. The company also
invests in an online learning platform for employees to refine or
develop their professional skills and explore new software to plan
their career growth.
Twist grants employees eight hours of paid time off each year
for volunteering. In fiscal 2022, Twist employees collectively
volunteered 592 hours for various causes and organizations. In
2022, Twist earned Great Place to Work® Certification™ in the U.S.
for the second consecutive year and for the first time in China,
Germany, Singapore, and the United Kingdom.
Commitment to Ethics and Security
Twist is dedicated to protecting the digital information of its
customers and employees. The company has robust cybersecurity and
biosecurity policies and systems in place, including an
International Organization for Standardization (ISO) certified
information security management system. Twist performs rigorous
biosecurity and export control screening to ensure that sequences
of DNA that could pose significant risk if misused are not
synthesized and shipped to unlicensed organizations. In addition,
Twist works with governments as well as other DNA synthesis
providers to develop, promote and evolve a consistent set of
biosecurity best practices. To maintain ethical practices across
the organization, Twist engages in red teaming and is meticulous in
keeping records, reporting, and in allocating personnel resources
to ensure that employees follow set policies and procedures.
To download the full report visit:
https://www.twistbioscience.com/company/esg?tab=environmental
1
Calculated Twist internal data
using Dr. Oligo benchmark January 2021
2
Calculated using the EPA
Greenhouse Gas Equivalencies Calculator
3
Data for US employee base
only
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
workforce reduction and reduced investments in DNA data storage;
the ability to attract new customers and retain and grow sales from
existing customers; the ability of Twist to achieve sufficient
revenue to achieve or maintain positive cash flow from operations
or profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 7,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230822647314/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925-202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024